[Elsevier] Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-10

Marilena Post time 2024-6-4 15:29:13 | Show all posts |Read mode
Reward10points

journal:Gynecologic Oncology

Authors:Dominique Berton; Patricia Pautier; Domenica Lorusso; Christine Gennigens; Laurence Gladieff; Anna Kryzhanivska; Jill Bowman; Chuan Tian; Mark Cornfeld; Toon Van Gorp

Published date:2024-7-

DOI:10.1016/j.ygyno.2024.05.025

PDF link:https://www.sciencedirect.com/sc ... 090825824002464/pdf

Article link:http://dx.doi.org/10.1016/j.ygyno.2024.05.025

Article Source:Elsevier BV


Remark:

Best Answer

Please adopt

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
Miyuki Post time 2024-6-4 15:29:14 | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    80

Latest Reply

Return to the list